Effectiveness of the Korean National Cancer Screening Program in Reducing Breast Cancer Mortality

2020 ◽  
Author(s):  
Eunji Choi ◽  
Jae Kwan Jun ◽  
Mina Suh ◽  
Kyu-Won Jung ◽  
Boyoung Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Cancer Screening Program

scholarly journals Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program

2016 ◽  
Vol 23 (4) ◽  
pp. 203-209 ◽  
Author(s):  
Solveig Hofvind ◽  
Marta Román ◽  
Sofie Sebuødegård ◽  
Ragnhild S Falk
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Cancer Death ◽  
Breast Cancer Death ◽  
Breast Cancer Screening Program ◽  
Cancer Screening Program

Objective To compute a ratio between the estimated numbers of lives saved from breast cancer death and the number of women diagnosed with a breast cancer that never would have been diagnosed during the woman’s lifetime had she not attended screening (epidemiologic over-diagnosis) in the Norwegian Breast Cancer Screening Program. Methods The Norwegian Breast Cancer Screening Program invites women aged 50–69 to biennial mammographic screening. Results from published studies using individual level data from the programme for estimating breast cancer mortality and epidemiologic over-diagnosis comprised the basis for the ratio. The mortality reduction varied from 36.8% to 43% among screened women, while estimates on epidemiologic over-diagnosis ranged from 7% to 19.6%. We computed the average estimates for both values. The benefit–detriment ratio, number of lives saved, and number of women over-diagnosed were computed for different scenarios of reduction in breast cancer mortality and epidemiologic over-diagnosis. Results For every 10,000 biennially screened women, followed until age 79, we estimated that 53–61 (average 57) women were saved from breast cancer death, and 45–126 (average 82) were over-diagnosed. The benefit–detriment ratio using average estimates was 1:1.4, indicating that the programme saved about one life per 1–2 women with epidemiologic over-diagnosis. Conclusion The benefit–detriment ratio estimates of the Norwegian Breast Cancer Screening Program, expressed as lives saved from breast cancer death and epidemiologic over-diagnosis, should be interpreted with care due to substantial uncertainties in the estimates, and the differences in the scale of values of the events compared.

Breast cancer mortality in Barcelona following implementation of a city breast cancer-screening program

2008 ◽  
Vol 32 (2) ◽  
pp. 162-167 ◽  
Author(s):  
Mariona Pons-Vigués ◽  
Rosa Puigpinós ◽  
Gemma Cano-Serral ◽  
Marc Marí-Dell’Olmo ◽  
Carme Borrell
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Breast Cancer Screening Program ◽  
Cancer Screening Program

scholarly journals Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program

Cancer ◽  
2013 ◽  
Vol 119 (17) ◽  
pp. 3106-3112 ◽  
Author(s):  
Solveig Hofvind ◽  
Giske Ursin ◽  
Steinar Tretli ◽  
Sofie Sebuødegård ◽  
Bjørn Møller
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Breast Cancer Screening Program ◽  
Cancer Screening Program

scholarly journals Breast cancer screening program in Lithuania: trends in breast cancer mortality before and during the introduction of the mammography screening programme

2020 ◽  
Vol 28 (2) ◽  
pp. 20-28
Author(s):  
Laura Steponavičienė ◽  
Rūta Briedienė ◽  
Rasa Vansevičiūtė-Petkevičienė ◽  
Daiva Gudavičienė ◽  
Ieva Vincerževskienė
Keyword(s):  
Breast Cancer ◽  
Cancer Mortality ◽  
Mammography Screening ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Target Population ◽  
Population Based ◽  
Cancer Awareness ◽  
Cancer Screening Program ◽  
Mammography Screening Program

BackgroundBreast cancer is the most frequent oncological disease as well as the leading cause of cancer death among women worldwide. Decline in mortality in economically strong countries is observed. This decline is mostly related to early diagnosis (improvement in breast cancer awareness and mammography screening program (MSP)) and more effective treatment. In the end of 2005, the MSP started in Lithuania. The main aim of this article was to evaluate breast cancer mortality during 22 years in Lithuania, as well as changes before the start of the MSP and during its implementation, in order to assess the influence of the MSP on mortality. Materials and MethodsAnalysis was based on data from the population-based Lithuanian Cancer Registry. Analysis of changes in mortality included the period from 1998 to 2019. Age standardized mortality rates were calculated for assessment of changes. Join-point regression analysis was used. ResultsApplying the segmental regression model, it was found that during the study period mortality was statistically significantly decreasing by -1.1% each year.  Mortality among women under the age of 50 decreased both before and during the implementation of MSP. Mortality in the target population also was already decreasing until the implementation of the program, but since 2006 significant reduction in mortality was observed in this group. ConclusionsOverall breast cancer mortality is decreasing in Lithuania. After the implementation of MSP the largest reduction in mortality was observed among the target population, however, it is not as pronounced as it could be with the well-organized MSP.

Profile of axillary nodal disease from the Irish National Breast Cancer Screening Program in the era of sentinel node biopsy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11629-e11629
Author(s):  
M. Barry ◽  
M. R. Kell
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Nodal Disease ◽  
Node Biopsy ◽  
Breast Cancer Screening Program ◽  
National Breast ◽  
Cancer Screening Program

e11629 Introduction: Ireland offers a socialized national breast cancer screening program (Breastcheck) to women between 50 and 65 years of age with the aim of reducing breast cancer mortality. Historical axillary staging for screen detected breast cancer has shown nodal positivity in 25% of cases. This study examines axillary nodal disease from the Irish national breast cancer screening program in the era of sentinel lymph node biopsy (SLNB). Methods: Patients with clinically and radiologically early stage screen detected breast cancer and negative axillae are offered therapeutic surgery with SLNB. We examined prospective Breastcheck data collected from 2006 and 2007. Results: 136,527 women attended for routine screening and from these 574 invasive breast cancers were detected. 55 (9.6%) were clinically/radiologically axillary node positive at diagnosis. 519 clinically node negative patients proceeded to therapeutic surgery with SLNB, 113 (22%) were found to have a positive SLNB. Overall nodal positivity was 29.3% in this asymptomatic population. We examined tumour characteristics, hormone profile and HER-2 status from the SLNB group and tumor size was the only factor significantly associated with a positive SLNB (20.1mm vs. 14.3mm, p, 0.01). Conclusions: SLNB accurately detects axillary nodal disease from a purely screen detected population. Based on historic data, SLNB is superior to axillary sampling in this population. No significant financial relationships to disclose.

scholarly journals Breast cancer screening with mammography in women aged 40–49 years: Impact of length of screening interval on effectiveness of the program

2020 ◽  
pp. 096914132091828
Author(s):  
Zheng Mao ◽  
Lennarth Nyström ◽  
Håkan Jonsson
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Interval Cancers ◽  
Screening Interval ◽  
Using Data ◽  
The Impact

Objectives To estimate the impact on the effectiveness of Swedish breast cancer screening program in women aged 40–49 years of shortening the screening interval from 21 months to 18 or 12 months. Methods The reduction in breast cancer mortality among participants in screening with mammography was previously estimated in the Swedish SCReening of Young women (SCRY) study to be 29%. The expected increased effectiveness with a hypothetical shorter screening interval than the average of 21 months in SCRY was calculated using data about the women who died from breast cancer even though they participated in the SCRY program. Results During the study period, 547 women who participated in the index screening round died from breast cancer. Shortening the screening interval to 18 months led to an improved effectiveness of 0.7–3.9% considering interval cancers only and of 1.3–7.6% considering screening-detected cancers only, and for both interval and screening-detected cancers the improvement was 1.9–11.5% when the assumed mortality reduction for the deceased cases varied from 5% to 30%. Shortening the screening interval to 12 months increased the effectiveness by 1.6–9.8% for interval cancers and by 2.9–17.4% for both interval and screening-detected cancers. Conclusion Shortening the screening interval for women aged 40–49 years to 18 or 12 months might further reduce the breast cancer mortality rate.

scholarly journals Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Eunji Choi ◽  
Jae Kwan Jun ◽  
Mina Suh ◽  
Kyu-Won Jung ◽  
Boyoung Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Mammographic Screening ◽  
Incidence Rates ◽  
Primary Study ◽  
Cancer Screening Program ◽  
Mortality Rate Ratio ◽  
Central Cancer Registry

AbstractHigh incidences of breast cancer (BC) are reported in Asian women in their forties, and it is not clear whether mammographic screening reduces mortality among them. This study evaluated the effect of BC screening on mortality in Korea. We conducted a nationwide prospective cohort study of women invited to the Korean National Cancer Screening Program (KNCSP) between 2002 and 2003 (N = 8,300,682), with data linkage to the Korea Central Cancer Registry and death certificates through 2014 and 2015, respectively. Exposure to mammographic screening was defined using a modified never/ever approach. The primary study outcome was adjusted mortality rate ratio (MRR) for BC among screened and non-screened women estimated by Poisson regression. An adjusted MRR for all cause-death other than BC was examined to account for selection bias in the cohort. BC incidence rates for screened and non-screened women were 84.41 and 82.88 per 100,000 women-years, respectively. BC mortality rates for screened and non-screened women were 5.81 and 13.43 per 100,000 women-years, respectively, with an adjusted MRR for BC of 0.43 (95% CI, 0.41−0.44). The adjusted MRR for all-cause death excluding BC was 0.52 (95% CI, 0.52−0.52). The greatest reduction in BC mortality was noted for women aged 45−54 years, and there was no observable reduction in mortality after the age of 70 years. In conclusion, the KNCSP has been effective in reducing BC mortality among Korean women aged 40−69 years.

The attendance of the second screening period (2004–2005) of the Hungarian organized breast cancer screening program

2008 ◽  
Vol 149 (32) ◽  
pp. 1491-1498 ◽  
Author(s):  
Imre Boncz ◽  
Andor Sebestyén ◽  
Lajos Döbrőssy ◽  
Zoltán Péntek ◽  
Attila Kovács ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Screening Program ◽  
Breast Cancer Screening Program ◽  
Cancer Screening Program

Célkitűzés: Az országos kiterjedésű, szervezett emlőszűrési program 2002 januárjában indult el Magyarországon a 45–65 év közötti nők számára 2 éves szűrési intervallummal. A dolgozat célja a szervezett emlőszűrési program részvételi mutatóinak meghatározása, beleértve a szűrési és diagnosztikus célú képalkotó emlőfelvételek gyakoriságának elemzését. Adatok és módszerek: Az elemzésben szereplő adatok az Országos Egészségbiztosítási Pénztár finanszírozási adatbázisából származnak, és a 2000–2005 közötti 6 évet ölelik fel. A 45–65 éves nők körében meghatározták azok arányát, akik a szervezett szűrést megelőző két évben (2000–2001), illetve a program első két ciklusában (2002–2003, 2004–2005) akár szűrési, akár diagnosztikai célú képalkotó emlővizsgálaton vettek részt. Eredmények: A szűrési célú képalkotó emlőfelvételen részt vettek aránya (átszűrtség) a 2000–2001-es 7,4%-ról a 2002–2003-as, illetve 2004–2005-ös szervezett emlőszűrési ciklusban 34,0, illetve 29,5%-ra emelkedett. A diagnosztikus célú képalkotó emlőfelvételen részt vettek aránya (átvizsgáltság) pedig ugyanezen időszakokban 19,8%-ról 22,1 (2002–2003), illetve 23,2%-ra (2004–2005) emelkedett. Az országos lefedettség (átszűrtség + átvizsgáltság) ennek megfelelően a szervezett szűrés hatására 26,2%-ról (2000–2001) 53,5%-ra (2002–2003), illetve 50,8%-ra (2004–2005) nőtt a vizsgált kétéves ciklusban a 45–65 év közötti nők esetében. Következtetés: A magyar emlőszűrési program kezdeti részvételi arányai 2004–2005-ben kissé csökkentek; az emlőrák miatti halálozás érdemi csökkentéséhez ennek emelése szükséges.

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

2021 ◽  
Vol 151 ◽  
pp. 106602
Author(s):  
Anouk H. Eijkelboom ◽  
Linda de Munck ◽  
Marc B.I. Lobbes ◽  
Carla H. van Gils ◽  
Jelle Wesseling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Incidence ◽  
Screening Program ◽  
Breast Cancer Incidence ◽  
Breast Cancer Screening Program ◽  
Cancer Screening Program
Sign in / Sign up

Export Citation Format

Share Document